All case studies

Highlights

We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.

Proactive patient retention strategy in a GLP-1 RA trial

Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.

A small biotech success story

A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.

FSP partnership - sustained efficiency and ongoing innovation

The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.

By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.

All case studies

Filter our case studies by categories, selecting amongst our broad range of solutions.

Study in type 1 diabetes patients

Sponsor proposed a randomized, open-label, multi-centre, parallel-group study comparing the safety and efficacy of STUDY DRUG with Novolog in type 1 diabetes (T1D) patients.

Severe COPD phase III case study

A sponsor conducting an international Phase III program of two double-blind, randomised studies consulted ICON’s respiratory experts for assistance in patient enrolment, and study planning and monitoring.

Complex, early-phase study in Huntington’s disease

ICON was contracted to conduct an early-phase clinical trial in Huntington’s disease across 12 countries and 53 sites.

Long-term follow-up study for rare disease gene therapy

ICON provided full-service support to a large biotech company in two global Phase 3 trials for a gene therapy product treating spinal muscular atrophy (SMA), a rare but serious condition causing muscle wasting and weakness.

Trial decentralisation

Clinical trial participation exposes rare disease participants to significant pressure financially, logistically and psychologically, and these incremental pressures can negatively impact a patient’s ability or willingness to enrol or remain in a clinical trial.

Rapid mobilisation to advance COVID-19 treatment development

In February 2020 ICON quickly mobilised its vaccine and infectious disease resources to assist government
and commercial clients in addressing the COVID-19 global threat.

Pivotal study in TBI

There are no specific pharmaceutical therapies available for TBI. Since 2001, ICON staff have participated in managing mult national TBI trials with several drugs including endopeptidase inhibitor and endothelin converting enzyme inhibitors, involving more than 1,000 TBI patients.

Pivotal NDA submission trial in ALS

ICON exceeded recruitment objectives within the initial recruitment timelines during COVID-19 pandemic.

RIM Data and System Assessment to ensure IDMP compliance

RIM System Configuration and Data Assessment is pivotal in regulatory business planning. It also helps in organising product registration process to track and manage all regulatory activities.

Early phase study for non-opioid pain treatment

A leading biotech company developing a groundbreaking non-opioid treatment for moderate-to-severe acute pain partnered with ICON to conduct a series of early-phase trials.

Overcoming activation and enrollment delays

ICON partnered with a drug development sponsor to conduct a global programme for Multiple sclerosis (MS) studies in over 2,200 patients.

Accelerated auxiliary medicine procurement for MASH trial

A biotechnology company required vitamin D distribution as an auxiliary medication for a phase 3 MASH and fibrosis clinical study. When the original supplement vendor was unable to support the study’s full global scope, the company engaged ICON’s Accelerated Pharmaceutical Solutions (APS) team to step in on short notice.

Solutions case studies

Our solutions span the entire lifecycle of product development and can be adapted to suit small local trials or large global programs. Explore our work in the different aspects of our solutions.

Let's collaborate

Discover how ICON's expertise transforms clinical trials.

Blogs

Stay informed with ICON's expert insights on clinical trials, regulatory changes, and industry trends. Our blogs provide practical advice, innovative solutions, and thought leadership from global experts.

News

Stay updated with our latest news on partnerships, financial results, technological advancements, and industry insights.

Insights

Explore ICON's expert analysis and practical advice on the latest operational, regulatory, technological and economic challenges in clinical research. Our insights provide thought leadership and innovative solutions to transform trials.

Case studies

Highlights

Proactive patient retention strategy in a GLP-1 RA trial

A small biotech success story

FSP partnership - sustained efficiency and ongoing innovation

All case studies

Study in type 1 diabetes patients

Severe COPD phase III case study

Complex, early-phase study in Huntington’s disease

Long-term follow-up study for rare disease gene therapy

Trial decentralisation

Rapid mobilisation to advance COVID-19 treatment development

Pivotal study in TBI

Pivotal NDA submission trial in ALS

RIM Data and System Assessment to ensure IDMP compliance

Early phase study for non-opioid pain treatment

Overcoming activation and enrollment delays

Accelerated auxiliary medicine procurement for MASH trial

Solutions case studies

Let's collaborate

Blogs

News

Insights